摘要
目的:观察莫西沙星与抗菌谱相近的阿奇霉素联合头孢哌酮/舒巴坦治疗社区获得性肺炎的临床疗效和安全性。方法:收集66例社区获得性肺炎患者,以随机抽样法分为2组。实验组(33例)给予莫西沙星注射液0.4 g,qd,静脉滴注;对照组(33例)给予阿奇霉素0.5 g,qd,联合头孢哌酮/舒巴坦2.5 g,bid,静脉滴注。结果:疗程结束后,2组在临床疗效、细菌清除率、不良反应方面比较,差异均无统计学意义(P>0.05)。结论:莫西沙星治疗社区获得性肺炎疗效确切,安全性与阿奇霉素联合头孢哌酮/舒巴坦相似。
OBJECTIVE： To evaluate the clinical efficacy and safety of moxifloxacin versus azithromycin （of similar antimicrobial spectrum ） plus cefoperazone/sulbactam in the treatment of community acquired pneumonia. METHODS ： 66 patients with community acquired pneumonia were randomized divided into 2 groups, of 33 each. Thetrial group received moxifloxacin （0.4 g, q. d） by iv gtt and the control group received azithromycin （0.5 g, q. d） plus cefoperazone/sulbactam （2.5 g, bid） by iv gtt. RESULTS ： After treatment completion, there were no statistical differences between the two groups in respect of therapeutic effect, bacterium clearance rate and adverse drug reactions （P 〉 0.05 ）. CONCLUSION： Moxifloxacin is proved to be effective and as safe as azithromycin plus cefoperazone/ sulbactam in the treatment of community acquired pneumonia.
出处
《中国医院用药评价与分析》
2012年第6期543-545,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
